Evidence map›Paper›PMID 28520672›Full record

Trial reportThe Journal of head trauma rehabilitation

Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial.

Jesse R Fann, Charles H Bombardier, Nancy Temkin, Peter Esselman, Catherine Warms, Jason Barber, Sureyya Dikmen

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of head trauma rehabilitation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 6 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 6 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jesse R FannDepartments of Psychiatry and Behavioral Sciences (Drs Fann and Dikmen), Rehabilitation Medicine (Drs Fann, Bombardier, Esselman, Warms, and Dikmen), and Neurological Surgery (Dr Temkin and Mr Barber), University of Washington School of Medicine, Seattle.
Charles H Bombardier
Nancy Temkin
Peter Esselman
Catherine Warms
Jason Barber
Sureyya Dikmen
Feminist Archive North · GB

Funding

CONTROLLED TRIAL OF SERTRALINE FOR DEPRESSION AFTER TBIR01HD039415 · NICHD · UNIVERSITY OF WASHINGTON · PI BOMBARDIER, CHARLES HENRY · 2000 to 2004
$2.6M
NICHD NIH HHS R01 HD039415
6 · The paper itself

Abstract

objectiveMajor depressive disorder (MDD) is common and associated with impaired functioning after traumatic brain injury (TBI). Few placebo-controlled antidepressant trials exist in this population. We evaluated the efficacy and tolerability of sertraline for MDD within 1 year of sustaining a TBI.

settingLevel I trauma center.

participantsAdults with MDD within 1 year of hospitalization for complicated mild to severe TBI.

designRandomized, double-blind, placebo-controlled trial. MAIN MEASURES: Twelve-week treatment response on the 17-item Hamilton Depression Rating Scale. We also assessed symptom improvement and remission.

resultsWe randomized 62 participants: 32% sustained a severe TBI, 68% had significant anxiety, 63% had a history of prior MDD, and 69% had a history of alcohol or drug dependence. Depression significantly improved from baseline to 12 weeks in both treatment groups (P < .001). There were no significant differences between the sertraline and placebo groups over 12 weeks on depression severity, response, or remission. The sertraline group had significant improvement on speed of information processing compared with the placebo group (P < .006).

conclusionSertraline monotherapy was not superior to placebo for MDD in people with post-acute complicated mild to severe TBI. Research is needed on the effectiveness of interventions that also address the significant psychosocial needs of this population.

Indexed as

AdultAntidepressive AgentsBrain Injuries, TraumaticDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansMajor Depressive DisorderMaleMiddle AgedMultivariate AnalysisPsychiatric Status Rating ScalesSertralineSeverity of Illness IndexAntidepressive AgentsSertraline

Identifiers

PMID28520672
PMCPMC5593759
OpenAlexW2616694829

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.